Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
NCT06863480
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Aneurysmal Subarachnoid Hemorrhage
Delayed Cerebral Ischemia
Interventions
DRUG:
tocilizumab-aazg (TYENNE)
Sponsor
University of Florida